|Day Low/High||121.00 / 122.47|
|52 Wk Low/High||55.00 / 133.62|
Eli Lilly and Incyte gave an update on rheumatoid arthritis drug baricitinib as Lilly unveiled second-quarter numbers that surpassed analyst estimates.
Incyte Corporation (Nasdaq:INCY) today announced that the first patient has been treated in GRAVITAS-301, a pivotal Phase 3 trial for the first-line treatment of patients with acute graft-versus-host disease (GVHD).
'Blind side' competition is playing havoc with some highly visible companies, says Jim Cramer. You can't compete with free.
Jim Cramer's bullish on Alexion Pharmaceuticals and Incyte. But, he says, Disney's good for the long term.
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 10:00 a.
Jim Cramer doesn't buy the backlash against Amazon. He says Prime is a very powerful tool and an irresistible bargain.
Jim Cramer is bullish on Citigroup, Zoetis, Idexx Labs, AbbVie, Nucor, and Alexion.
- Pooled analysis of eight clinical trials shows no difference in serious infection events compared to placebo
Jim Cramer is bullish on Domino's Pizza, Xylem, and Incyte, but he's waiting for better pricing for NXP Semiconductor.
Jim Cramer says the markets could be further rattled by the Federal Reserve meeting.
Lilly to share 31 abstracts, including 27 abstracts detailing safety, efficacy and patient outcomes data for Olumiant and Taltz
Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.
Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: Goldman Sachs 38 th Annual Global Healthcare Conference on Wednesday,...
Credit Suisse analyst Alethia Young isn't worried about Incyte.
Incyte Corporation (Nasdaq:INCY) announced today that data from ongoing investigational studies of epacadostat in combination with pembrolizumab (ECHO-202) and nivolumab (ECHO-204) in multiple tumor types will be discussed...
Incyte Corporation (Nasdaq:INCY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced updated data from the ongoing Phase 1/2 ECHO-204 trial evaluating the safety and efficacy of epacadostat, Incyte's investigational...
Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that updated data from the ongoing Phase 1/2 ECHO-202 trial evaluating epacadostat, Incyte's...
Incyte's actions are another reminder that biotech companies carefully groom and manage the clinical data they want investors to see, even at important, open medical meetings like ASCO.
Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated data from the advanced non-small cell lung cancer (NSCLC) patient cohort of the ongoing Phase...
Incyte and Merck are combining two cancer immunotherapy drugs to treat patients with non-small cell lung cancer.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARR, AYA, CMCT, CRMT, INCY, NMR Downgrades: ASC, CPLP, FITB, MTRX, PAM Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: William Blair 2017 Growth Stock Conference on Wednesday, June 14, 2017...
Jim Cramer makes the calls on Tanger Factory Outlet Centers, Gilead Sciences, and Qorvo in the 'Mad Money' Lightning Round.
Ahead of Fed's June meeting, investors will need to start paying close attention to Fed officials and economic data.
Jim Cramer is bullish on Walgreens Boots Alliance, Becton Dickinson, and General Mills.
Money managers are piling back into growth stocks without hesitation, says Jim Cramer.
Wall Street snaps back to gains on Thursday as positive earnings from Walmart help distract from brewing trouble in Washington, D.C.